Technical Analysis for MESO - Mesoblast Limited

Grade Last Price % Change Price Change
F 8.51 -0.58% -0.05
MESO closed down 0.58 percent on Friday, April 9, 2021, on 32 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical MESO trend table...

Date Alert Name Type % Chg
MACD Bullish Signal Line Cross Bullish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.58%
NR7 Range Contraction -0.58%
Inside Day Range Contraction -0.58%
Up 3 Days in a Row Strength -0.58%
Oversold Stochastic Weakness -0.58%
20 DMA Resistance Bearish 0.59%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.59%
Older End-of-Day Signals for MESO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Mesoblast Limited Description

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative therapeutic cell-based products in Australia, the United States, and Singapore. The company is developing therapeutic products using its proprietary technology platforms, which include mesenchymal lineage adult stem cells (MLCs) to treat conditions with unmet medical needs, including cardiac diseases, spine and musculoskeletal disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. Its lead product candidates comprise MPC-150-IM for congestive heart failures; MPC-06-ID to treat chronic lower back pain due to moderate degenerative disc diseases; MSC-100-IV for the treatment of steroid refractory acute graft versus host diseases (GVHDs); and MPC-300-IV for biologic refractory rheumatoid arthritis and diabetic nephropathy. The company is also developing JR-031 for pediatric and adult GVHDs; MPC-25-IC, which is in Phase II clinical trial to treat acute cardiac ischemia; MPC-25-Osteo that has been completed Phase II clinical trial for the treatment of spinal fusion; and MPC-CBE, which is in Phase III clinical trial to treat bone marrow transplantations. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its MPCs for cardiovascular diseases and neurologic conditions. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Pharmaceutical Industry Bone Stem Cells Hematology Therapeutic Product Proprietary Technology Rheumatoid Arthritis Cardiovascular Disease Therapeutic Products Heart Failure Spine Vascular Diseases Cardiovascular Diseases Pharmaceutical Industries Transplantation Bone Marrow Diabetic Nephropathy Adult Stem Cell Cell Product Ischemia Back Pain Congestive Heart Failure Host Disease Skeletal Disorders Spinal Fusion Teva Pharmaceutical Industries Graft Versus Host Disease Mesoblast Host Diseases Inflammatory Conditions Regenerative Biomedicine Bone Marrow Transplantation Cardiac Diseases Degenerative Disc Disease Musculoskeletal Disorders

Is MESO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 21.28
52 Week Low 4.1
Average Volume 301,858
200-Day Moving Average 12.40
50-Day Moving Average 9.32
20-Day Moving Average 8.85
10-Day Moving Average 8.43
Average True Range 0.41
ADX 17.98
+DI 15.25
-DI 21.90
Chandelier Exit (Long, 3 ATRs ) 8.62
Chandelier Exit (Short, 3 ATRs ) 9.34
Upper Bollinger Band 9.84
Lower Bollinger Band 7.85
Percent B (%b) 0.33
BandWidth 22.49
MACD Line -0.29
MACD Signal Line -0.30
MACD Histogram 0.01
Fundamentals Value
Market Cap 1 Billion
Num Shares 118 Million
EPS -0.91
Price-to-Earnings (P/E) Ratio -9.35
Price-to-Sales 101.32
Price-to-Book 3.30
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.85
Resistance 3 (R3) 8.85 8.73 8.79
Resistance 2 (R2) 8.73 8.65 8.73 8.78
Resistance 1 (R1) 8.62 8.59 8.56 8.62 8.76
Pivot Point 8.51 8.51 8.48 8.51 8.51
Support 1 (S1) 8.39 8.42 8.34 8.40 8.26
Support 2 (S2) 8.28 8.37 8.28 8.24
Support 3 (S3) 8.17 8.28 8.23
Support 4 (S4) 8.17